Skip to main content

Table 3 Treatment Administration

From: Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

  Dose Group 1 Dose Group 2  
Safety Population 2000/10 mg 2500/10 mg Total
No. of Patients 13 6 19
Total No. of Cycles Administered 56 23 79
Median No. of Cycles per Patient (Range) 4 (1−14) 3.5 (1−7) 4 (1−14)
No. of Cycles with Dose Reduction (% of total cycles) 4 (7) 3 (13) 7 (9)
No. of Cycles with Dose Delay (% of total cycles) 7 (13) 3 (13) 10 (13)